HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.

Abstract
Experimental autoimmune uveoretinitis (EAU) is a T helper type 1 cell-mediated autoimmune disease, which serves as a model of human chronic uveitis. In this model, cells of a monocyte/macrophage lineage and retinal antigen (Ag)-specific T cells infiltrate into the retina and cause inflammatory lesion, where proinflammatory cytokines and various stimuli activate a transcriptional factor, nuclear factor-kappaB (NF-kappaB), which modulates inflammation and enhances immune responses. In the present study, the therapeutic effect of administration of a NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), was examined in a murine EAU model. It was shown that PDTC ameliorated the clinical symptoms of EAU mice and significantly reduced the histopathological score compared with those in untreated mice. mRNA expressions of tumor necrosis factor alpha and interleukin-1beta were suppressed in eyes of PDTC-treated EAU mice. However, when T cells from PDTC-treated EAU mice, Ag-presenting cells (APC), and the retinal Ag peptides were cocultured, these T cells showed the same level of proliferation as those from control mice. Furthermore, addition of PDTC in the culture of T cells from EAU mice, Ag, and APC completely abrogated the T cell-proliferative response and cytokine production. Pretreatment of Ag-primed T cells or APC with PDTC in vitro also reduced these responses. These results indicate that the inhibitory effect of PDTC is attributed mainly to the suppression of effector-phase responses including inflammation but not to the inhibition of T cell priming. Regulation of NF-kappaB pathway in the lesion could be a novel target for the successful control of uveoretinitis.
AuthorsHirokuni Kitamei, Kazuya Iwabuchi, Kenichi Namba, Kazuhiko Yoshida, Yoshiki Yanagawa, Nobuyoshi Kitaichi, Mizuki Kitamura, Shigeaki Ohno, Kazunori Onoé
JournalJournal of leukocyte biology (J Leukoc Biol) Vol. 79 Issue 6 Pg. 1193-201 (Jun 2006) ISSN: 0741-5400 [Print] England
PMID16574770 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantigens
  • Eye Proteins
  • Interleukin-1
  • Interleukins
  • NF-kappa B
  • Peptide Fragments
  • Pyrrolidines
  • RNA, Messenger
  • Rela protein, mouse
  • Retinol-Binding Proteins
  • Thiocarbamates
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • interstitial retinol-binding protein
  • pyrrolidine dithiocarbamic acid
Topics
  • Amino Acid Sequence
  • Animals
  • Antigen-Presenting Cells (immunology)
  • Autoantigens (chemistry, immunology, toxicity)
  • Cell Division (drug effects)
  • Crosses, Genetic
  • Drug Evaluation, Preclinical
  • Eye Proteins (chemistry, immunology)
  • Female
  • Gene Expression Regulation (drug effects)
  • Interleukin-1 (biosynthesis, genetics)
  • Interleukins (biosynthesis, genetics)
  • Lymphocyte Activation (drug effects)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred Strains
  • Molecular Sequence Data
  • NF-kappa B (antagonists & inhibitors)
  • Nervous System Autoimmune Disease, Experimental (drug therapy)
  • Peptide Fragments (immunology, toxicity)
  • Protein Transport (drug effects)
  • Pyrrolidines (pharmacology, therapeutic use)
  • RNA, Messenger (biosynthesis)
  • Retinitis (drug therapy)
  • Retinol-Binding Proteins (chemistry, immunology)
  • T-Cell Antigen Receptor Specificity
  • T-Lymphocyte Subsets (immunology)
  • Thiocarbamates (pharmacology, therapeutic use)
  • Transcription Factor RelA (analysis, antagonists & inhibitors)
  • Tumor Necrosis Factor-alpha (biosynthesis, genetics)
  • Uveitis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: